Weight loss drug and heart ablation study for AFib
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This trial tests whether a weight loss medication (semaglutide) given before and after a first-time heart ablation procedure for atrial fibrillation can improve outcomes. It is for people who are overweight or obese and have certain related health conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are scheduled for your first heart ablation for atrial fibrillation.
- You have a body mass index (BMI) of 30 or higher, OR a BMI of 27 or higher along with conditions like prediabetes, type 2 diabetes, high blood pressure, high cholesterol, heart or blood vessel disease, or sleep apnea.
- If you could become pregnant, you must have a negative pregnancy test and agree to use highly effective birth control during the study.
- You cannot have had a prior heart ablation or be currently using certain diabetes medications like GLP-1 agonists, dual agonists, or DPP-IV inhibitors.
- You do not have severe kidney, liver, or heart failure, a history of pancreatitis, or type 1 diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking semaglutide (a once-weekly injection for weight loss) before a heart procedure called catheter ablation helps people with atrial fibrillation. It may help those with excess weight or obesity who have not used this type of medication before.
This trial tests whether the drug tirzepatide (used for weight loss) can help reduce the return of atrial fibrillation after a catheter ablation procedure. It is for people with persistent AFib who are overweight and have another weight-related health condition.
This trial tests whether tirzepatide, a medication for weight and blood sugar, can reduce the chances of atrial fibrillation (an irregular heartbeat) coming back after a heart procedure called catheter ablation in people with overweight or obesity. It may help by addressing weight-related factors that contribute to heart rhythm problems.
This study tests whether a medicine called dapagliflozin can reduce abnormal electrical activity in the heart by targeting fat around the heart in people with atrial fibrillation who are scheduled for a first catheter ablation. It may help improve the success of the procedure.
This study tests if a weight management program helps people with a new type of irregular heartbeat (atrial fibrillation) and obesity. It aims to see if losing weight can improve heart rhythm and reduce the need for further treatment.
This study tests whether a weekly injection of semaglutide (the same drug in Wegovy and Ozempic) can help people with atrial fibrillation lose weight and improve their heart condition. It's for people with AF who also have obesity, and may or may not plan to have a heart procedure called catheter ablation.
Hear when a new Obesity & Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.